SCHEMBL3127079

SCHEMBL3127079

CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)c(OC(C)=O)c2)C(C)C(C)C)cc1OC(C)=O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
GAA P10253 1/20 0.49
RAB9A P51151 1/20 0.49
TOP1 P11387 2/20 0.41
CFD P00746 2/20 0.40
ALOX15 P16050 4/20 0.40
NR3C1 P04150 1/20 0.39
TNFSF11 O14788 1/20 0.39
GAPDH P04406 1/20 0.38
JUN P05412 1/20 0.38
NFKB1 P19838 1/20 0.38
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
HIF1A Q16665 1/20 0.38
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9052230 0.86 TSHR (0.49) TSHRGAANR3C1TNFSF11JUN
SCHEMBL8741805 0.85 TSHR (0.46) TSHRALDH1A1ALOX15NR3C1TNFSF11
SCHEMBL3127157 0.84 ALOX15 (0.59) ALDH1A1KDM4EGAAALOX15LMNA
SCHEMBL2356556 0.83 ALDH1A1 (0.57) ALDH1A1ALOX15LMNACYP3A4HIF1A
SCHEMBL3936561 0.82 TSHR (0.55) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL18930164 0.82 TSHR (0.55) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL178987 0.82 TSHR (0.55) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL2308033 0.81 ALOX15 (0.61) ALDH1A1KDM4EGAAALOX15LMNA
SCHEMBL8231214 0.80 KDM4E (0.56) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL7658156 0.79 TSHR (0.51) TSHRALDH1A1KDM4EGAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2961412-A1 CANCER THERAPY Triact Therapeutics, Inc. (US) 2016-01-06 EP disclosed
WO-2014134202-A1 CANCER THERAPY TRIACT THERAPEUTICS, INC. (US) 2014-09-04 WO disclosed
WO-2010054264-A1 USE OF CATECHOLIC BUTANE DERIVATIVES IN CANCER THERAPY TRIACT THERAPEUTICS, INC. (US) 2010-05-14 WO disclosed
EP-0297733-A2 Pharmaceutical compositions comprising catecholic butanes BLOCK DRUG COMPANY, INC. (US) 1989-01-04 EP disclosed